PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018

  • Pages: 311
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Dec, 2017
  • SKU: DISR0001
  • Single User License
    (20% Off)
    $3,250.00
  • Site License
    (30% Off)
    $6,500.00
  • Global License
    (40% Off)
    $9,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors. This Report provides comprehensive insights across PD-1 and PD-L1 Inhibitors including detailed Marketed product profiles.
The report has information on detailed pipeline portfolio including Phase III, Phase II, Phase I, Pre-Clinical and Discovery Products. With more than 50 products in various stages of development, the pipeline seems encouraging which has made PD-1 and PD-L1 the most talked about Immuno-oncology target. There are 50+products in pipeline and 5 products have been marketed so far. The focus is majorly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells to restore latent anti-tumor immunity.                                                                                                                                                                   

KEY COVERAGE AND BENEFITS:
1. In-depth analysis of the 50+ pipeline assets.
2. Pipeline landscape provides a deep dive into clinical, pre-clinical and discovery molecules.
3. Extensive coverage of Technology implemented by companies in this space.
4. Licensing and Deals related to PD-1 and PD-L1 inhibitors are also covered.
5. Insights on marketed products including detailed marketed product profiles. Also includes Historical and Five years forecasted sales for Marketed products (Opdivo, Keytruda,Tecentriq, Bavencio and Imfinzi).
6. Extensive coverage of ASCO 2017 updates and related insights.
7. Therapeutic assessment by molecule type, route of administration, monotherapy and combination products.
8. Detailed information on inactive projects in the pipeline for PD-1 & PD-L1 Inhibitors.
9. Information to identify emerging players with potentially lucrative products.

  1. Executive Summary
  2. Technology
  3. Product Type by Specificity
  4. ASCO 2017 Highlights
  5. Programmed Death 1 (PD-1)
  6. Programmed Death Ligand 1 (PD-L1)
  7. Role of PD-1 and PD-L1 pathways
  8. MOA of PD-1 and PD-L1 inhibitors
  9. Significance of PD-1 and PD-L1 inhibitors
  10. PD-1 and PD-L1 Active Therapy Areas & Epidemiology
  11. Biomarkers - PD-1 and PD-L1 inhibitors
  12. Major issues with PD-L1 as a Biomarker
  13. Market Overview
  14. Comparative Analysis of Pipeline & Marketed Products
  15. Marketed Drug Candidate Profiles
  16. ASCO 2017 Updates
  17. Pipeline Therapeutics
  18. Comparative Analysis
  19. Late Stage Products (Phase III)
  20. Comparative Analysis
  21. Late Stage(Phase III) ProductProfiles
  22. Mid Stage Products (Phase II)
  23. Comparative Analysis
  24. Mid Stage(Phase II) ProductProfiles
  25. Early Stage Products (Phase I and IND)
  26. Comparative Analysis
  27. Early Stage(Phase I and IND) Product Profiles
  28. Pre-clinical and Discovery Stage Products
  29. Comparative Analysis
  30. Pre-clinical and Discovery Stage Product Profiles
  31. Therapeutic Assessment: Active Products
  32. Assessment by Monotherapy Products
  33. Assessment by Route of Administration
  34. Assessment by Stage and Route of Administration
  35. Assessment by Molecule Type
  36. Assessment by Stage and Molecule Type
  37. Dormant Products
  38. Comparative Analysis
  39. Appendix

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical and Discovery Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Combination Products
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Dormant Products

Figure 1: Illustration: T cell interaction with cancer
Figure 2: Illustration: PD-L1/PD-1 Pathway
Figure 3: Illustration: MOA of PD-1 and PD-L1
Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
Figure 6: Late Stage Products (Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I)
Figure 9: Pre-clinical Stage and Discovery Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Dormant Products

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.